Medtronic PLC $MDT Shares Bought by CSM Advisors LLC

CSM Advisors LLC raised its position in Medtronic PLC (NYSE:MDT) by 13.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 285,260 shares of the medical technology company’s stock after buying an additional 33,167 shares during the quarter. CSM Advisors LLC’s holdings in Medtronic were worth $27,169,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Ausdal Financial Partners Inc. purchased a new position in shares of Medtronic during the third quarter worth approximately $391,000. California Public Employees Retirement System increased its holdings in shares of Medtronic by 57.9% in the 3rd quarter. California Public Employees Retirement System now owns 5,101,347 shares of the medical technology company’s stock valued at $485,852,000 after acquiring an additional 1,870,495 shares during the period. Chilton Investment Co. Inc. raised its position in Medtronic by 4.4% in the 3rd quarter. Chilton Investment Co. Inc. now owns 208,283 shares of the medical technology company’s stock valued at $19,837,000 after purchasing an additional 8,790 shares during the last quarter. Boothbay Fund Management LLC raised its position in Medtronic by 14.2% in the 3rd quarter. Boothbay Fund Management LLC now owns 2,694 shares of the medical technology company’s stock valued at $257,000 after purchasing an additional 335 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in Medtronic by 41.8% during the 3rd quarter. Alliancebernstein L.P. now owns 7,921,480 shares of the medical technology company’s stock worth $754,442,000 after purchasing an additional 2,333,686 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Down 0.4%

Shares of Medtronic stock opened at $87.05 on Friday. The company has a market cap of $111.77 billion, a P/E ratio of 24.25, a PEG ratio of 2.23 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33. The firm has a fifty day moving average of $97.96 and a two-hundred day moving average of $96.87.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the previous year, the firm earned $1.38 earnings per share. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MDT. Morgan Stanley raised their price objective on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Jefferies Financial Group reiterated a “hold” rating and set a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Truist Financial lowered their price target on Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a report on Wednesday, February 18th. Needham & Company LLC restated a “buy” rating and issued a $120.00 price target on shares of Medtronic in a research report on Tuesday. Finally, JPMorgan Chase & Co. reduced their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).